Your browser doesn't support javascript.
Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19.
Qin, Jingru; Guo, Chao; Yang, Lu; Liang, Xiao; Jiao, Aijun; Lai, Keng Po; Yang, Bin.
  • Qin J; College of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
  • Guo C; Department of Pharmacy, Guigang City People's Hospital, the Eighth Affiliated Hospital of Guangxi Medical University, Guigang, Guangxi, PR China.
  • Yang L; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, PR China.
  • Liang X; College of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
  • Jiao A; College of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
  • Lai KP; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, PR China.
  • Yang B; College of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
Bioengineered ; 12(2): 12461-12469, 2021 12.
Article in English | MEDLINE | ID: covidwho-1585255
ABSTRACT
Severe mortality due to the COVID-19 pandemic resulted from the lack of effective treatment. Although COVID-19 vaccines are available, their side effects have become a challenge for clinical use in patients with chronic diseases, especially cancer patients. In the current report, we applied network pharmacology and systematic bioinformatics to explore the use of biochanin A in patients with colorectal cancer (CRC) and COVID-19 infection. Using the network pharmacology approach, we identified two clusters of genes involved in immune response (IL1A, IL2, and IL6R) and cell proliferation (CCND1, PPARG, and EGFR) mediated by biochanin A in CRC/COVID-19 condition. The functional analysis of these two gene clusters further illustrated the effects of biochanin A on interleukin-6 production and cytokine-cytokine receptor interaction in CRC/COVID-19 pathology. In addition, pathway analysis demonstrated the control of PI3K-Akt and JAK-STAT signaling pathways by biochanin A in the treatment of CRC/COVID-19. The findings of this study provide a therapeutic option for combination therapy against COVID-19 infection in CRC patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / Anticarcinogenic Agents / Genistein / Phytoestrogens / COVID-19 Type of study: Diagnostic study / Prognostic study Topics: Vaccines Language: English Journal: Bioengineered Year: 2021 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / Anticarcinogenic Agents / Genistein / Phytoestrogens / COVID-19 Type of study: Diagnostic study / Prognostic study Topics: Vaccines Language: English Journal: Bioengineered Year: 2021 Document Type: Article